IL-12 drug for metastatic cancer after checkpoint therapy
Part of Cancer clinical trials.
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 80 years old and can sign consent before any study steps.
- You have advanced or metastatic solid cancer that has been proven by lab tests (biopsy or similar).
- Your cancer got worse after an approved immune checkpoint medicine, and you have already received a checkpoint-based treatment plan.
- You must have had disease control on the checkpoint drug (such as stable disease) and then later showed progression on scans.
- You are well enough to participate (ECOG 0–2) and are expected to live at least 12 weeks.
- Your blood counts and organ function are adequate, and past treatment side effects have largely healed (mostly back to Grade 1 or better).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new treatment that uses your own immune cells, modified to produce IL-12, to fight solid tumors that have come back or not responded to other therapies. It aims to see if this approach is safe and can shrink or control cancer.
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.